PDS Biotechnology is an immunotherapy company developing molecularly targeted immunotherapies designed to overcome the limitations of existing immunotherapy and vaccine technologies. Co.'s T cell activating platforms designed to train the immune system to attack and destroy disease; Versamune®, and Versamune plus PDS0301 for treatments in oncology; and Infectimune, for treatments in infectious disease. Co. develops targeted product candidates to treat several cancers including Human Papillomavirus-associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Co.'s infectious disease candidates are of potential interest for use in COVID-19 and universal influenza vaccines. The PDSB YTD return is shown above.
The YTD Return on the PDSB YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether PDSB YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PDSB YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|